- $766.88m
- $537.68m
- $0.58m
Brief: Icosavax Reports First Quarter 2023 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Icosavax, U.S. solar companies, Nikola, energy firms
Icosavax gains after update on RSV vaccine trial
Brief: Icosavax Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Corporate Update
Brief: Icosavax Q4 basic EPS USD -0.59
Brief: Icosavax Granted FDA Fast Track Designation For IVX-A12
Jefferies bullish on Icosavax's RSV vaccine data in 2023
Icosavax set for best day on promising data from RSV vaccine trial
Icosavax jumps on promising data update for RSV vaccine trial
Brief: Icosavax Inc - Ivx-121 Continues To Be Generally Well Tolerated With No Safety Concerns Observed In This Six-Month Follow Up
Brief: Icosavax Reports Third Quarter Financial Results
Brief: Icosavax Initiates Phase 1 Trial Of IVX-A12 Against RSV And hMPV In Older Adults
Brief: Icosavax Inc Files For Mixed Shelf Of Up To $400 Million - SEC Filing
U.S. RESEARCH ROUNDUP- Aptinyx, Rapid Micro Biosystems, Trinet Group
Brief: Icosavax Reports Q2 2022 Results
U.S. STOCKS ON THE MOVE-Exxon Mobil, Tesla, energy firms
Icosavax falls after COVID vaccine candidate component found to be unstable
Brief: Icosavax Announces Results From IVX-411 Drug Product Investigation
NASDAQ RESUMED AT 09:47 AM